Symbiotec Pharmalab is launching its initial public offering (IPO) on August 24, aiming to raise ₹1,757 crore. The price band for the shares is set between ₹938 and ₹988, with the subscription window open until August 27. Retail investors must invest a minimum of ₹14,820 to participate in the offering, according to livemint.com.
The IPO is expected to attract significant interest, with the grey market premium (GMP) standing at ₹320 as of August 21. This suggests the stock could list at a premium of approximately 32.4% over the upper price band of ₹988. The GMP reflects investor enthusiasm ahead of the subscription period, indicating strong demand for Symbiotec Pharmalab shares, livemint.com reported.
Symbiotec Pharmalab operates in the pharmaceutical sector, and its IPO adds to the growing number of healthcare companies seeking public funding in India. The ₹1,757 crore target places it among notable mid-sized offerings this year, highlighting continued investor appetite for pharma stocks. The listing premium implied by the GMP aligns with recent trends where well-positioned pharma firms have seen robust market reception.
The IPO subscription closes on August 27, with the company expected to finalize allotments shortly thereafter. The listing date has not been officially announced but will follow standard regulatory timelines. Investors and market watchers will closely monitor the listing performance, given the strong GMP signal and sector interest, as reported by livemint.com.